vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and KKR Real Estate Finance Trust Inc. (KREF). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $25.8M, roughly 1.4× KKR Real Estate Finance Trust Inc.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -101.7%, a 98.1% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -26.6%). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -18.8%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.

GYRE vs KREF — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.4× larger
GYRE
$37.2M
$25.8M
KREF
Growing faster (revenue YoY)
GYRE
GYRE
+60.0% gap
GYRE
33.4%
-26.6%
KREF
Higher net margin
GYRE
GYRE
98.1% more per $
GYRE
-3.7%
-101.7%
KREF
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
-18.8%
KREF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GYRE
GYRE
KREF
KREF
Revenue
$37.2M
$25.8M
Net Profit
$-1.4M
$-26.2M
Gross Margin
95.3%
Operating Margin
0.3%
-105.1%
Net Margin
-3.7%
-101.7%
Revenue YoY
33.4%
-26.6%
Net Profit YoY
-340.1%
-229.6%
EPS (diluted)
$-0.01
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
KREF
KREF
Q4 25
$37.2M
$25.8M
Q3 25
$30.6M
$25.3M
Q2 25
$26.8M
$30.2M
Q1 25
$22.1M
$31.3M
Q4 24
$27.9M
$35.1M
Q3 24
$25.5M
$37.0M
Q2 24
$25.2M
$40.4M
Q1 24
$27.2M
$39.1M
Net Profit
GYRE
GYRE
KREF
KREF
Q4 25
$-1.4M
$-26.2M
Q3 25
$5.9M
$13.8M
Q2 25
$1.6M
$-29.7M
Q1 25
$3.7M
$-4.9M
Q4 24
$569.0K
$20.3M
Q3 24
$2.9M
$-7.4M
Q2 24
$4.5M
$25.8M
Q1 24
$9.9M
$-3.1M
Gross Margin
GYRE
GYRE
KREF
KREF
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
GYRE
GYRE
KREF
KREF
Q4 25
0.3%
-105.1%
Q3 25
22.7%
50.4%
Q2 25
8.1%
-101.3%
Q1 25
10.3%
-18.3%
Q4 24
2.4%
55.8%
Q3 24
16.6%
-19.6%
Q2 24
12.7%
63.3%
Q1 24
29.7%
-8.7%
Net Margin
GYRE
GYRE
KREF
KREF
Q4 25
-3.7%
-101.7%
Q3 25
19.4%
54.4%
Q2 25
5.9%
-98.5%
Q1 25
16.9%
-15.5%
Q4 24
2.0%
57.7%
Q3 24
11.2%
-20.0%
Q2 24
18.0%
63.9%
Q1 24
36.6%
-7.9%
EPS (diluted)
GYRE
GYRE
KREF
KREF
Q4 25
$-0.01
$-0.49
Q3 25
$0.03
$0.12
Q2 25
$0.00
$-0.53
Q1 25
$0.00
$-0.15
Q4 24
$0.00
$0.22
Q3 24
$0.01
$-0.19
Q2 24
$0.01
$0.29
Q1 24
$0.03
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
KREF
KREF
Cash + ST InvestmentsLiquidity on hand
$52.4M
$84.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$106.0M
$1.2B
Total Assets
$166.1M
$6.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
KREF
KREF
Q4 25
$52.4M
$84.6M
Q3 25
$60.0M
$204.1M
Q2 25
$54.4M
$107.7M
Q1 25
$29.9M
$106.4M
Q4 24
$26.7M
$104.9M
Q3 24
$25.1M
$108.8M
Q2 24
$25.1M
$107.2M
Q1 24
$37.4M
$106.5M
Stockholders' Equity
GYRE
GYRE
KREF
KREF
Q4 25
$106.0M
$1.2B
Q3 25
$101.9M
$1.2B
Q2 25
$92.0M
$1.2B
Q1 25
$68.1M
$1.3B
Q4 24
$63.3M
$1.3B
Q3 24
$63.2M
$1.4B
Q2 24
$60.4M
$1.4B
Q1 24
$56.6M
$1.4B
Total Assets
GYRE
GYRE
KREF
KREF
Q4 25
$166.1M
$6.5B
Q3 25
$159.4M
$6.5B
Q2 25
$152.6M
$6.8B
Q1 25
$129.8M
$6.6B
Q4 24
$125.4M
$6.4B
Q3 24
$125.2M
$6.8B
Q2 24
$120.9M
$7.1B
Q1 24
$122.0M
$7.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
KREF
KREF
Operating Cash FlowLast quarter
$-5.6M
$72.3M
Free Cash FlowOCF − Capex
$-5.8M
FCF MarginFCF / Revenue
-15.5%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
KREF
KREF
Q4 25
$-5.6M
$72.3M
Q3 25
$4.7M
$18.5M
Q2 25
$2.1M
$21.1M
Q1 25
$-129.0K
$15.9M
Q4 24
$-2.8M
$132.6M
Q3 24
$1.7M
$49.1M
Q2 24
$-5.5M
$30.6M
Q1 24
$2.9M
$34.5M
Free Cash Flow
GYRE
GYRE
KREF
KREF
Q4 25
$-5.8M
Q3 25
$4.0M
Q2 25
$1.8M
Q1 25
$-251.0K
Q4 24
$-2.8M
Q3 24
$1.0M
Q2 24
$-6.9M
Q1 24
$2.7M
FCF Margin
GYRE
GYRE
KREF
KREF
Q4 25
-15.5%
Q3 25
13.1%
Q2 25
6.8%
Q1 25
-1.1%
Q4 24
-10.1%
Q3 24
4.1%
Q2 24
-27.5%
Q1 24
9.8%
Capex Intensity
GYRE
GYRE
KREF
KREF
Q4 25
0.4%
Q3 25
2.2%
Q2 25
1.0%
Q1 25
0.6%
Q4 24
0.2%
Q3 24
2.7%
Q2 24
5.8%
Q1 24
0.9%
Cash Conversion
GYRE
GYRE
KREF
KREF
Q4 25
Q3 25
0.79×
1.34×
Q2 25
1.32×
Q1 25
-0.03×
Q4 24
-4.85×
6.54×
Q3 24
0.60×
Q2 24
-1.21×
1.19×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons